Trial Profile
A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms STRENGTH
- Sponsors AstraZeneca
- 15 Nov 2020 Primary endpoint (The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.) has not been met.
- 15 Nov 2020 Results published in the JAMA: the Journal of the American Medical Association.
- 30 Jul 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.